Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III ma...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Reardon, David A., Herndon, James E., Peters, Katherine, Desjardins, Annick, Coan, April, Lou, Emil, Sumrall, Ashley, Turner, Scott, Sathornsumetee, Sith, Rich, Jeremy N., Boulton, Susan, Lipp, Eric S., Friedman, Henry S., Vredenburgh, James J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3403724/
https://ncbi.nlm.nih.gov/pubmed/21997879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0740-0
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια